Cat. No. | Product name | CAS No. |
DC66697 | 2-Thioxothiazolidine-4-carboxylic Acid Featured | 20933-67-9 |
DC66698 |
STING agonist-12
Featured
STING agonist-12 (Compound 53) is a potent, orally active human STING activator with an EC50 of 185 nM. |
2259624-71-8 |
DC66699 |
Sacituzumab govitecan
Featured
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity. |
1491917-83-9 |
DC66700 |
(S,R)-LSN3318839
Featured
(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). |
2765539-92-0 |
DC66701 | (3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol Featured | 151953-64-9 |
DC66702 |
Farletuzumab
Featured
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. |
896723-44-7 |
DC66703 | Dompe patent anti-FOLR1 Featured | |
DC66704 | BMS-986012 Featured | |
DC66705 |
Vantictumab
Featured
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
1345009-45-1 |
DC66706 | U.Toronto patent anti-FZD7 Featured | |
DC60641 |
CD-005
Featured
CD-005 is a low-molecular-weight gelator that can be used to prepare gels for proteins and vaccines. CD-005 can physically entrap proteins, preventing their irreversible aggregation, and maintain protein function for at least 4 weeks even at temperatures up to 50°C. |
105462-53-1 |
DC66707 |
Casdatifan
Featured
Casdatifanum is a hypoxia-inducible factor (HIF) inhibitor. |
2709069-30-5 |
DC66708 |
BMS-986408
Featured
BMS-986408 is a DGK inhibitor. |
2618418-12-3 |
DC66709 |
BAY-2925976
Featured
BAY-2925976 is an ARα2C antagonist. |
2642235-06-9 |
DC66710 |
AZD4144
Featured
AZD4144 is an NLRP3 inhibitor. |
2890191-41-8 |
DC66711 |
CHF-6523
Featured
CHF-6523 is an inhaled PI3Kδ inhibitor. |
|
DC66712 | BAY-2413555 Featured | |
DC66713 | NVP-EVS459 Featured | |
DC60642 |
Compound 33 (HYOU1 inhibitor)
Featured
Compound 33 (HYOU1 inhibitor) is a first-in-class inhibitor of hypoxia up-regulated protein 1 (HYOU1) with EC50 of 3.2 μM/2.6 μM/16.1 μM/3.0 μM in WT-MIP3/WT-RANTES/hTNFtg-MIP3/hTNFtg-RANTES, respectively. |
|
DC60643 |
BRD-810
Featured
BRD-810 is a potent and selective MCL1 inhibitor with Kd of 0.3 nM (SPR) and IC50 of 0.4 nM (MCL1-Noxa HTRF), respectively. BRD-810 is a rapidly cleared inhibitor of MCL1 that has robust antitumor efficacy in hematological and solid tumor cancer models. |
|
DC60644 |
ERAS-0015
Featured
ERAS-0015 is a pan-RAS modulator glue and demonstrates siganificantly more potent inhibition of cellular proliferation across KRAS mutant cell lines vs RMC-6236. |
|
DC60645 |
CBPD-409
Featured
CBPD-409 is a highly potent, selective and orally bioavailable PROTAC degrader of CBP/p300. CBPD-409 induces robust CBP/p300 degradation with DC50 0.2-0.4 nM and displays strong antiproliferative effects with IC50 1.2-2.0 nM in the VCaP, LNCaP, and 22Rvl AR+ prostatcancer cell lines. |